125 related articles for article (PubMed ID: 9885435)
1. Idiopathic myelofibrosis: a clinical review.
Manoharan A
Int J Hematol; 1998 Dec; 68(4):355-62. PubMed ID: 9885435
[TBL] [Abstract][Full Text] [Related]
2. Idiopathic myelofibrosis: pathogenesis to treatment.
Reilly JT
Hematol Oncol; 2006 Jun; 24(2):56-63. PubMed ID: 16477581
[TBL] [Abstract][Full Text] [Related]
3. Idiopathic myelofibrosis: pathogenesis, natural history and management.
Reilly JT
Blood Rev; 1997 Dec; 11(4):233-42. PubMed ID: 9481452
[TBL] [Abstract][Full Text] [Related]
4. Myelofibrosis revisited: characterization and classification of myelofibrosis in the setting of myeloproliferative disease.
Gilbert HS
Prog Clin Biol Res; 1984; 154():3-17. PubMed ID: 6382299
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis and management of idiopathic myelofibrosis.
Reilly JT
Baillieres Clin Haematol; 1998 Dec; 11(4):751-67. PubMed ID: 10640215
[TBL] [Abstract][Full Text] [Related]
6. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
Gregory SA; Mesa RA; Hoffman R; Shammo JM
Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
[TBL] [Abstract][Full Text] [Related]
7. Myelofibrosis: a concise review of clinical and pathologic features and treatment.
Smith RE; Chelmowski MK; Szabo EJ
Am J Hematol; 1988 Nov; 29(3):174-80. PubMed ID: 3055953
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Myelofibrosis: A Moving Target.
Cerquozzi S; Farhadfar N; Tefferi A
Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
[TBL] [Abstract][Full Text] [Related]
9. Myelofibrosis: clinicopathologic features, prognosis, and management.
O'Sullivan JM; Harrison CN
Clin Adv Hematol Oncol; 2018 Feb; 16(2):121-131. PubMed ID: 29741513
[TBL] [Abstract][Full Text] [Related]
10. Myelofibrosis: a review of clinical and pathologic features and treatment.
Smith RE; Chelmowski MK; Szabo EJ
Crit Rev Oncol Hematol; 1990; 10(4):305-14. PubMed ID: 2278639
[TBL] [Abstract][Full Text] [Related]
11. Idiopathic myelofibrosis--an update with particular reference to clinical aspects and prognosis.
Hasselbalch HC
Int J Clin Lab Res; 1993; 23(3):124-38. PubMed ID: 8400333
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis.
Anderson JE; Sale G; Appelbaum FR; Chauncey TR; Storb R
Br J Haematol; 1997 Sep; 98(4):1010-6. PubMed ID: 9326205
[TBL] [Abstract][Full Text] [Related]
13. [Myeloproliferative disorders].
Binder D; Fehr J
Ther Umsch; 2004 Feb; 61(2):131-42. PubMed ID: 15018396
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic options for patients with myelofibrosis in blast phase.
Mascarenhas J; Navada S; Malone A; Rodriguez A; Najfeld V; Hoffman R
Leuk Res; 2010 Sep; 34(9):1246-9. PubMed ID: 20627294
[TBL] [Abstract][Full Text] [Related]
15. New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.
Palandri F; Auteri G; Baccarani M
Hematol Oncol; 2017 Jun; 35(2):145-150. PubMed ID: 27510853
[TBL] [Abstract][Full Text] [Related]
16. Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options.
Mesa RA; Barosi G; Cervantes F; Reilly JT; Tefferi A
Best Pract Res Clin Haematol; 2006; 19(3):495-517. PubMed ID: 16781486
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.
Alchalby H; Kröger N
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S36-41. PubMed ID: 25486953
[TBL] [Abstract][Full Text] [Related]
18. Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia.
Martyré MC
Curr Hematol Rep; 2003 May; 2(3):257-63. PubMed ID: 12901348
[TBL] [Abstract][Full Text] [Related]
19. Primary myelofibrosis: update on definition, pathogenesis, and treatment.
Abdel-Wahab OI; Levine RL
Annu Rev Med; 2009; 60():233-45. PubMed ID: 18947294
[TBL] [Abstract][Full Text] [Related]
20. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.
Martyré MC
Leuk Lymphoma; 1995 Dec; 20(1-2):39-44. PubMed ID: 8750621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
